%0 Journal Article
%T Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients
%A Alexandra S. Whale
%A Alistair G. Reid
%A Alona Sosinsky
%A Dalia Kasperaviciute
%A Dragana Milojkovic
%A Gareth Gerrard
%A Jane Apperley
%A Jim F. Huggett
%A Letizia Foroni
%A Martin Forbes
%A Mary Alikian
%A Michael Mueller
%A Peter Ellery
%J The Journal of Molecular Diagnostics
%D 2016
%R 10.1016/j.jmoldx.2015.09.005
%X Recent studies indicate that 40% of chronic myeloid leukemia patients who achieve
sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor therapy remain
disease-free after drug discontinuation. In contrast, 60% experience return of detectable
disease and have to restart treatment, thus highlighting the need for an improved
method of identifying patients with the lowest likelihood of relapse. Here we describe
the validation of a personalized DNA-based digital PCR (dPCR) approach for quantifying
very low levels of residual disease, which involves the rapid identification of t(9;22)
fusion junctions using targeted next-generation sequencing coupled with the use of
a dPCR platform.
%U https://jmd.amjpathol.org/article/S1525-1578(15)00265-2/fulltext